Isoniazid Clinical Use
Isoniazid is primarily used for the treatment of latent tuberculosis infection (LTBI) to prevent progression to active TB disease, and as a first-line agent in combination therapy for active tuberculosis. 1, 2
Primary Indications
Latent Tuberculosis Infection (LTBI)
Isoniazid reduces the risk of developing active TB disease in persons with documented LTBI, identified through positive tuberculin skin testing (TST) or interferon-gamma release assays 1. The drug is effective across multiple populations:
- HIV-negative adults and children with positive TST (≥5mm in high-risk groups, ≥10mm in moderate-risk groups, ≥15mm in low-risk individuals under 35) 1, 2
- HIV-positive persons with positive TST, though benefit is uncertain in those with negative TST in low TB incidence settings 1
- Recent TST converters (≥10mm increase within 2 years for those <35 years; ≥15mm increase for ≥35 years) 2
- Close contacts of infectious TB cases, particularly children and adolescents who are tuberculin-negative initially but require prophylaxis until repeat testing 2
High-Risk Populations Requiring LTBI Treatment
Isoniazid is indicated for persons with specific medical conditions that increase TB risk (all with ≥10mm TST) 2:
- Silicosis or fibrotic pulmonary lesions consistent with healed TB (requires 12 months of therapy)
- Diabetes mellitus
- Chronic renal disease or end-stage renal disease
- Immunosuppressive therapy or hematologic malignancies
- Conditions causing rapid weight loss or chronic malnutrition
- HIV infection (≥5mm TST threshold)
- Injection drug users
Active Tuberculosis
Isoniazid serves as a cornerstone first-line agent in combination regimens for active TB disease 2. It works by inhibiting mycolic acid synthesis in the bacterial cell wall and is bactericidal against actively growing intracellular and extracellular Mycobacterium tuberculosis 2.
Dosing Regimens for LTBI
The 2020 CDC/NTCA guidelines establish preferred and alternative regimens 1:
Preferred Shorter-Course Regimens
- 3 months of once-weekly isoniazid plus rifapentine (3HP) - strongly recommended for most patients 3
- 4 months of daily rifampin - alternative preferred option
- 3 months of daily isoniazid plus rifampin - effective as 6-9 months of isoniazid monotherapy 1
Alternative Longer Regimens
- 6 months of daily isoniazid - strongly recommended for HIV-negative patients, conditionally for HIV-positive 1
- 9 months of daily isoniazid - conditionally recommended, possibly more effective than 6 months though direct comparison data are lacking 1
- 12 months for patients with fibrotic lesions or silicosis 2
Critical Safety Considerations
Hepatotoxicity Risk
Isoniazid-induced liver injury represents the most significant adverse effect, with risk increasing with age, particularly over 35 years 1, 2, 4. The 2020 guidelines emphasize:
- Monthly monitoring (in-person or telephone) to assess adherence and adverse effects 3
- Baseline liver function tests for high-risk patients: HIV infection, pre-existing liver disease, postpartum period (≤3 months), regular alcohol use, injection drug use 3, 2
- Discontinuation if AST ≥5× upper limit of normal without symptoms, or ≥3× with symptoms 3
Populations Requiring Enhanced Monitoring 2:
- Daily alcohol users
- Age >35 years
- Active chronic liver disease
- Women in minority groups, particularly postpartum
- HIV-seropositive patients
- Concurrent chronic medications
Other Adverse Effects
- Peripheral neuropathy - more common with high doses; pyridoxine supplementation recommended 2
- Systemic drug reactions with 3HP regimen - approximately 5% discontinue due to flu-like symptoms, typically after first 3-4 doses 3
- Drug interactions - isoniazid affects metabolism of carbamazepine, phenytoin, theophylline, valproate, and warfarin; rifapentine reduces hormonal contraceptive effectiveness 3, 2
Important Clinical Caveats
Active TB disease must be excluded before initiating LTBI treatment - isoniazid monotherapy rapidly induces resistance if active disease is present 2. This requires clinical evaluation and chest radiography at minimum.
For HIV-positive persons in high TB incidence areas, isoniazid plus antiretroviral therapy is more effective than either alone in preventing TB disease 1.
Treatment completion rates are modest - only 64% complete at least 6 months in real-world settings, with lower rates in homeless individuals, those with excess alcohol use, and those experiencing adverse effects 5. The shorter 3HP regimen addresses this adherence challenge.
Recent evidence questions high-dose isoniazid for MDR-TB - a 2025 study found 93.1% of MDR-TB isolates exhibited high-level isoniazid resistance, suggesting clinicians should reconsider this approach due to suboptimal effect and toxicity concerns 6.
Pharmacokinetic variability is significant - NAT2 acetylator phenotype substantially affects clearance, with slow acetylators having higher drug levels and potentially increased toxicity risk 2, 7. However, this does not significantly alter effectiveness for standard LTBI treatment 2.